Financings Of The Fortnight: Corporate Venture Plays Increased Role In Series A Financings
This article was originally published in The Pink Sheet Daily
Executive Summary
More than one-quarter of biopharma or diagnostic start-ups that raised A rounds in the past 18 months had participation by one or more corporate venture arms. Plus news on recent financings by Esperion Therapeutics, XO1, PTC Therapeutics and Valeant.
You may also be interested in...
Anticoagulant Maker XO1 Takes $11M In Index Ventures’ Largest Series A
A chance discovery at a U.K. hospital led to the synthesis of an antibody that could prevent blood clots without causing excessive bleeding. Index Ventures created and funded single-asset company XO1 to conduct first-in-man tests on the compound by 2015.
Aiming For Non-Statin Cholesterol Drug Market, Esperion Takes $33M
Spun out from Pfizer five years ago, the Ann Arbor, Mich., company hopes its Phase II candidate can capture a share of the market for high-cholesterol drugs prescribed to statin-intolerant patients.
Cystic Fibrosis Market Snapshot: Disease-Modifying Drugs Elusive 24 Years After Discovery Of Root Cause
The discovery in 1989 of the underlying genetics causing cystic fibrosis was expected to spur broad development of disease-modifying therapies. As of 2013, however, only one such drug is on the market, for a small subset of CF patients, and a few other candidates are in clinical development.